Analysts Offer Predictions for RCKT FY2025 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Rocket Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the biotechnology company will post earnings per share of ($3.20) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $65.00 price target on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.07.

A number of other equities research analysts have also issued reports on the company. Jefferies Financial Group initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, December 18th. They issued a “buy” rating and a $29.00 target price for the company. Wedbush started coverage on shares of Rocket Pharmaceuticals in a research report on Monday, December 30th. They set an “outperform” rating and a $32.00 target price on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $39.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Chardan Capital reissued a “buy” rating and issued a $62.00 price objective on shares of Rocket Pharmaceuticals in a research report on Monday, November 18th. Finally, Scotiabank initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $50.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Rocket Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $47.27.

Rocket Pharmaceuticals Stock Up 5.7 %

Shares of NASDAQ RCKT opened at $11.08 on Thursday. The stock has a fifty day moving average price of $12.39 and a 200 day moving average price of $16.88. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals has a 12-month low of $10.07 and a 12-month high of $31.47. The company has a market cap of $1.01 billion, a P/E ratio of -4.03 and a beta of 1.01.

Insiders Place Their Bets

In other news, CEO Gaurav Shah sold 11,091 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $13.05, for a total transaction of $144,737.55. Following the completion of the transaction, the chief executive officer now directly owns 707,328 shares of the company’s stock, valued at approximately $9,230,630.40. This represents a 1.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 13,490 shares of company stock valued at $176,045. Company insiders own 28.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Rocket Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,292 shares of the biotechnology company’s stock worth $61,000 after acquiring an additional 582 shares during the period. KBC Group NV boosted its position in shares of Rocket Pharmaceuticals by 159.6% during the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company’s stock worth $69,000 after buying an additional 3,366 shares during the period. Values First Advisors Inc. bought a new position in Rocket Pharmaceuticals in the 3rd quarter worth approximately $108,000. SG Americas Securities LLC acquired a new stake in Rocket Pharmaceuticals in the 3rd quarter valued at approximately $113,000. Finally, Dana Investment Advisors Inc. boosted its position in Rocket Pharmaceuticals by 4.4% during the 2nd quarter. Dana Investment Advisors Inc. now owns 13,847 shares of the biotechnology company’s stock worth $298,000 after acquiring an additional 586 shares during the period. 98.39% of the stock is currently owned by institutional investors.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.